https://doi.org/10.55788/017187ab
“The addition of tobacco treatment to lung cancer screening reduces deaths by an additional 14%, providing a fantastic opportunity to make real health gains [2],” argued Prof. Rachael Murray (University of Nottingham, UK). “However, it remains unclear what type of smoking cessation intervention will elicit the largest effect.” The current study invited 2,150 eligible participants who were scheduled for a lung health check to visit a co-located smoking cessation practitioner (SCP) through an opt-out system. Of the eligible participants, 1,609 agreed to receive ongoing support by the SCP and 1,003 were randomised into the YESS trial (NCT03750110). In the control arm, participants received behavioural support plus pharmacotherapy (n=476), whereas participants in the intervention arm (n=527) received the support of the control arm plus personalised feedback and supportive communication. After 4 weeks, 3 months, and 12 months, smoking status was assessed (7-day validated point prevalence).
Abstinence from smoking was 16.5% after 4 weeks, between 30.0–33.6% after 3 months, and between 28.6–29.2% after 12 months of support by the SCP, with no significant differences between the control group and the intervention group. However, a significant interaction effect was observed for sex after 3 months; the intervention with personalised supportive care appeared to be more effective in women than in men (OR 1.70 vs 0.82; P=0.002); this effect was maintained at 12 months. Prof. Murray highlighted that cessation rates around 30% are high, which indicates the benefit of co-located and ongoing smoking support. Also, cessation rates are higher after 3 months than after 4 weeks, suggesting that participants may not be ready to quit smoking at the time of the lung health check, but that continued support by an SCP leads to high cessation rates in time.
- Murray RL, et al. Adding co-located, personalised stop smoking support to a lung cancer screening programme: The Yorkshire Enhanced Stop Smoking study (YESS). PL03.03, WCLC 2022, Vienna, Austria, 06–09 August.
- Cao P, et al. J Thorac Oncol. 2020 Jul;15(7):1160-1169.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Do we underestimate the effect of air pollution on lung cancer incidence? Next Article
Early detection strategies in younger patients with lung cancer are urgently needed »
« Do we underestimate the effect of air pollution on lung cancer incidence? Next Article
Early detection strategies in younger patients with lung cancer are urgently needed »
Table of Contents: WCLC 2022
Featured articles
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
WCLC 2022 Congress Round-Up
Sugemalimab offers PFS benefits for unresectable NSCLC
First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
NADIM: Risk of progression identified through RNA sequencing
NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?
First DLL3-targeted therapy shows promise in SCLC
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Pembrolizumab plus lenvatinib performs well in MPM
Early detection strategies in younger patients with lung cancer are urgently needed
Intensive co-located smoking cessation programme highly effective during lung screening
Do we underestimate the effect of air pollution on lung cancer incidence?
Interventions needed to address sexual health in lung cancer
Related Articles
November 16, 2022
A pathway from air pollution to lung cancer in non-smokers identified
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com